Global EditionASIA 中文雙語Fran?ais
    Business

    US biotech firm bullish on Chinese business

    By ZHOU WENTING in Shanghai | CHINA DAILY | Updated: 2019-11-28 00:00
    Share
    Share - WeChat

    US biotech company Amgen is aiming at rapid development of its business in China by bringing in more bone and inflammation therapies to build on its robust annual growth in the country.

    The enormous growth this year came mainly from the launch of a biologic injection to treat cardiovascular disease, and the product was moving much faster than anticipated, Penny Wan, vice-president and general manager of Amgen Japan, Australia and Asia-Pacific, said during an interview with China Daily.

    "We estimate we will see triple-digit growth in China this year," Wan said.

    China is absolutely on top of the worldwide agenda of the company, which started its business in the country in 2012 and has two products for three indications so far, Wan said.

    "For China, two out of every five deaths are due to cardiovascular diseases. We see our solution as fitting for the Chinese community and we want to move really fast to help those patients," she said.

    Annual rankings by the Genetic Engineering & Biotechnology News, a US-based industry journal, showed Amgen was ranked first among biopharmaceutical companies in the world for 2019 for the second time. It is one of the world's largest independent biotechnology companies, with its headquarters located in Thousand Oaks, California.

    At the beginning of this month, the company announced it was in the process of closing a deal with BeiGene, a Beijing-based domestic biomedicine enterprise. The deal is awaiting regulatory approval.

    "We are accelerating our momentum to building a more robust and complete portfolio in our key China market. Such strategic collaboration with local leading players is aimed to expand our oncology presence in China and to jointly advance Amgen's oncology pipeline in China and globally," Wan said.

    Amgen wants to accelerate the transformation of its healthcare model from disease treatment to prevention through collaboration with multiple stakeholders to help the country achieve the Healthy China 2030 initiative.

    In the area of bone health, a major issue in an aging society, it is trying to work with different partners to help prevent falls and fractures for people with low bone density.

    Statistics from the National Health Commission last year showed that the rate of osteoporosis among Chinese people aged 50 and older was 19.2 percent.

    "With aging, the number one challenge is what if people lose their mobility when they fall, have fractured bones, and then they can potentially become dependent," Wan said, adding that one in three patients with a hip fracture dies within 12 months.

    The disease presents a heavy economic burden for families and the society. Figures from the International Osteoporosis Foundation showed that medical bills caused by hip fractures totaled more than $9 billion in China in 2010, and are forecast to more than double to nearly $20 billion in 2035.

    "So we're working with partners to promote prevention ahead of treatment of a hip fracture. It's a better option for osteoporosis patients to receive treatment for osteoporosis so that they don't break their bones," Wan explained.

    She said the company is gearing up to launch an injection product taken every six months to help increase bone density and prevent fractures for people in the Chinese market.

    "We have specific plans and are conducting active discussions with the regulatory authorities to bring the project into the country," Wan said.

    Today's Top News

    Editor's picks

    Most Viewed

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    无码无遮挡又大又爽又黄的视频| 欧美视频中文字幕| 中文字幕视频在线免费观看| 国产乱人无码伦av在线a| 特级做A爰片毛片免费看无码| 精品国产v无码大片在线观看| 亚洲国产中文字幕在线观看 | 国产网红主播无码精品| 中文成人无字幕乱码精品区| 丰满熟妇乱又伦在线无码视频| 国产aⅴ无码专区亚洲av麻豆| av区无码字幕中文色| 手机永久无码国产AV毛片| 无码H黄肉动漫在线观看网站 | 国产av无码专区亚洲av果冻传媒 | 国产拍拍拍无码视频免费 | 国产亚洲精品无码专区| 亚洲av无码国产精品色午夜字幕 | 中文字幕在线观看亚洲日韩| 一本大道久久东京热无码AV| 国产a v无码专区亚洲av| 精品无码AV一区二区三区不卡| 亚洲精品无码av人在线观看 | 亚洲日产无码中文字幕| 无码人妻丰满熟妇啪啪网站| 久久五月精品中文字幕| 亚洲综合日韩中文字幕v在线| 日韩av无码中文字幕| 一本一道AV无码中文字幕| 亚洲精品无码专区久久同性男| 久久激情亚洲精品无码?V| 久久99久久无码毛片一区二区 | 日韩精品无码Av一区二区| 国产仑乱无码内谢| 亚洲?V无码成人精品区日韩 | 亚洲韩国—中文字幕| 中文字幕亚洲综合久久2| 亚洲日本va午夜中文字幕久久 | 亚洲色中文字幕无码AV| 亚洲AV无码第一区二区三区| 人妻丰满AV无码久久不卡|